LR Health & Beauty SE Reports First Half of 2025 Results and Adjusts 2025 Forecast

LR Health & Beauty SE has announced its financial results for the first half of 2025 and adjusted its annual forecast. The company achieved sales of EUR 142.9 million, a slight decrease of 0.3% from last year due to subdued consumer sentiment, particularly in Western Europe. EBITDA improved by 13.6% to EUR 13.3 million despite increased marketing and sales costs affecting the financial outlook.

A new leadership team, including CEO Jörg Körfer and interim CFO Ante Franicevic, is focusing on strategic development amidst these challenges. They are initiating discussions with bondholders regarding adjustments to the 2024/2028 bond terms to manage potential covenant breaches.

The company has revised its sales and earnings guidance for 2025, now anticipating stable sales rather than slight growth. EBITDA is expected to range between EUR 24 million and EUR 27 million. The adjustments come as business costs continue to rise, impacting previous financial predictions.